Vivoryon Therapeutics NV (WBO:VVYN) Current Accrued Expense: € Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WBO:VVYN Vivoryon Therapeutics NV WBO:VVYN
15 GF Score
Price €1.11
! 2 Warning Signs
View Full Analysis

What is Vivoryon Therapeutics NV Current Accrued Expense?

Vivoryon Therapeutics NV WBO:VVYN -0.45% 15 Current Accrued Expense is € Mil as of Jun. 2026. GuruFocus rates WBO:VVYN with a GF Score™ of 15/100. The stock has 2 warning signs investors should review.

Vivoryon Therapeutics NV's Current Accrued Expense for the quarter that ended in Jun. 2026 was € Mil.

Vivoryon Therapeutics NV Current Accrued Expense Related Terms

Vivoryon Therapeutics NV Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Vivoryon Therapeutics NV's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivoryon Therapeutics NV Current Accrued Expense Chart

Vivoryon Therapeutics NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Vivoryon Therapeutics NV Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -
WBO:VVYN
15GF Score
Vivoryon Therapeutics NV WBO:VVYN
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vivoryon Therapeutics NV Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of € Mil mean?
Vivoryon Therapeutics NV (WBO:VVYN) has a Current Accrued Expense of € Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Vivoryon Therapeutics NV and its competitors.
Is Vivoryon Therapeutics NV's Current Accrued Expense too high?
Vivoryon Therapeutics NV's current Current Accrued Expense is € Mil. Overall, Vivoryon Therapeutics NV has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Vivoryon Therapeutics NV's Current Accrued Expense compare to VRTX and REGN?
Vivoryon Therapeutics NV's Current Accrued Expense of € Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Vivoryon Therapeutics NV and its competitors. Vivoryon Therapeutics NV's current Current Accrued Expense is € Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivoryon Therapeutics NV stock overvalued right now?
Vivoryon Therapeutics NV (WBO:VVYN) has a current Current Accrued Expense of € Mil. The current Current Accrued Expense is € Mil. Vivoryon Therapeutics NV's overall GF Score™ is 15/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Vivoryon Therapeutics NV (WBO:VVYN), the current Current Accrued Expense is € Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Vivoryon Therapeutics NV Business Description

Address Weinbergweg 22, Halle, SN, DEU, 06120
Vivoryon Therapeutics NV is a clinical-stage biopharmaceutical company focused on discovering, developing, and potentially commercializing small-molecule-based medicines that modulate the activity and stability of pathologically altered proteins. Vivoryon is currently focused on developing treatments for chronic kidney disease (CKD), and more precisely, is initially targeting stage 3b and worse diabetic kidney disease (DKD). Its product pipeline includes various drug candidates, including varoglutamstat (PQ912), VY2149, and NCE, as potential treatments for chronic kidney disease (CKD), and more precisely, are initially targeting stage 3b and worse diabetic kidney disease (DKD). The company is also pursuing antibody-based approaches for Alzheimer's disease.
15GF Score

Get the complete analysis for WBO:VVYN

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.11
Price